SPDR S&P Biotech

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

Revolution Medicines Pancreatic Cancer Drug Trial Shows Positive Results, US Cancer Center Launches Expanded Access Plan Amid Stock Fluctuation

Madrigal Pharmaceuticals Reports Q1 2026 Net Loss Widens to $94.39M Despite Strong Rezdiffra Revenue Amidst Uncertainty

Bank of America Analyst Maintains Buy Rating on Travere Therapeutics with $50 Target Price

Travere Therapeutics Completes $525 Million Convertible Note Issuance for Refinancing and Operations

US Clinics Race to Enroll Patients in Revolution Medicines Pancreatic Cancer Drug Early Access Plan After FDA Approval

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Travere Therapeutics Receives 'Modest Buy' Consensus Rating from Thirteen Analysts

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Travere Therapeutics issues convertible notes and repurchases existing convertible notes

Celldyne Announces New Data Release for MYQORZO® at the 2026 European Heart Failure Conference

Cytokinetics Announces Aficamten Superior to Metoprolol in Phase III Study

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Travere Therapeutics Insider Sells Shares, Raises Short-Term Sell Pressure Concerns

Cytokinetics Prices Expanded Public Offering, Expected to Raise $700 Million

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

CICC Cuts ZAI LAB  TP to HKD20.2; 1Q Results In Line

ZLAB

LABU

CICC has reduced ZAI LAB's target price to HKD20.2 following a report indicating a 6% YoY revenue decline to USD99.6 million and a net loss of USD51 million in 1Q. The results met expectations. The broker highlighted ongoing Phase III trials and multiple candidates entering clinical stages. CICC adjusted its 2026 and 2027 earnings forecasts, predicting larger net losses, while maintaining an Outperform rating.

- CICC reported that ZAI LAB (09688.HK) had a revenue of USD 99.6 million in Q1, a 6% YoY decline, with a net loss of USD 51 million, aligning with expectations.  
- The company is advancing its pipeline, with Zoci in Phase III trials and ZL1503 and ZL6201 in earlier clinical stages, while recent earnings forecasts have been downgraded due to competitive pricing pressures.  
- CICC lowered the 2026 net loss projection for ZAI LAB from USD 226 million to USD 248 million and maintained an Outperform rating, reducing the target price by 8%.

AASTOCKS News

Zai Lab

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

VG Health

ZAI LAB

CICC

BAYN

BAYRY

ARKG

SBIO

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

PUBT

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

Wave Life Sciences announced positive results from the RestorAATion-2 trial, showing that WVE-006 effectively restores M-AAT levels and reduces Z-AAT levels. In the 200 mg biweekly cohort, M-AAT reached 64% of total, while Z-AAT decreased by 71%. The 400 mg monthly dosing also showed significant results. The treatment was well tolerated with no liver toxicities. The company anticipates FDA feedback on accelerated approval by mid-2026 and plans to present further data in H2 2026.

TradingView

Wave Life Sciences

Proshares Ultra Nasdaq Biotech

Bioshares Biotech Clinical Trials Fd

Wave Life Sciences posts positive RestorAATion-2 data; WVE-006 restores M-AAT, cuts Z-AAT, supports monthly dosing

NTHI

NeOnc Technologies Holdings, Inc. reported progress in its glioma programs, completing a Phase 1 study of NEO212 and enrolling in a Phase 2a trial of NEO100. The company improved its financial position with a $10 million PIPE financing and reduced its quarterly net loss to $8.8 million. Analysts rate NTHI stock as a Buy with a $20.00 target, though concerns about financial performance persist. NeOnc focuses on CNS cancers, developing drugs under FDA Fast-Track status.

Tip Ranks

Neonc Tech

NeOnc Advances Glioma Programs and Strengthens Financial Position

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Goldman Sachs

GS Hldg R

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

REGN

The FDA has granted breakthrough therapy designation to baxdrostat for uncontrolled hypertension, a significant milestone for patients. Meanwhile, the agency faces instability with leadership departures, raising concerns about regulatory consistency. Additionally, Regeneron has entered a multibillion-dollar collaboration with Parabilis Medicines to develop new therapeutic candidates using AI-driven drug discovery.

Pharmexec

Regeneron Pharma

AstraZeneca

Invesco Nasdaq Biotechnology ETF

<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>

IBRX

ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Laboratory. The agreement allows ImmunityBio to develop, conduct clinical trials, and manage regulatory approvals for 10 years post-FDA approval, with no upfront payments required. After approval, ImmunityBio must purchase at least two batches annually. The deal also includes rights for certain ex-U.S. territories.

ImmunityBio

ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory

Barclays analyst Charles Pitman maintained a Buy rating on Bayer with a price target of €50.00. Pitman has a 4-star rating with an average return of 11.4%. UBS also rated Bayer as a Buy, while Deutsche Bank issued a Hold rating on the same day.

Barclays

UBS Group AG

Deutsche Bank AG

Deutsche Bank AG Subscription Rights

Deutsche Postbank AG

Barclays Remains a Buy on Bayer (0P6S)

ImmunityBio has secured exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG for bladder cancer treatment, addressing a long-standing supply shortage. The partnership follows positive Phase 3 trial results, and ImmunityBio will be the sole applicant for FDA approval. Additionally, the company has obtained five U.S. patents related to its ANKTIVA and BCG treatment, enhancing its intellectual property protection until at least 2035.

benzinga_article

S&P 500

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

Regeneron has entered a strategic collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis's Helicon peptide platform, targeting historically 'undruggable' proteins. The deal includes $50 million upfront and a $75 million investment commitment, totaling $125 million initially, with potential milestone payments of up to $2.2 billion. The collaboration aims to create a new class of therapeutics, Antibody-Helicon Conjugates, combining Regeneron's antibodies with Helicons to target intracellular proteins.

<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>

Took some profit out of $T-Rex 2X Long HOOD Daily Target ETF(ROBN.US) and $SPDR S&amp;P Biotech(XBI.US) still own shares in both.Source: Sunrise Trader

T-Rex 2X Long HOOD Daily Target ETF

• Market rally hesitates due to escalating tensions in the Strait of Hormuz. • $Palantir Tech(PLTR.US)'s Q1 earnings and revenue exceeded estimates, driven by growth in its U.S. government business. • $SPDR S&amp;P Biotech(XBI.US) shows strength. • Lattice Semiconductor $Lattice Semicon(LSCC.US) and $ON Semiconductor(ON.US) Semiconductor both reported strong earnings, but ON's stock dropped. • $Grayscale Bitcoin Mini Trust ETF(BTC.US) approaches $80,000 following a compromise on the Clarity Act regarding stablecoin yields. • $Eli Lilly(LLY.US) recovered after a patient experienced liver failure from its weight-loss pill. • $Mirum Pharmaceuticals(MIRM.US) shares surged to an all-time high due to positive liver disease treatment results.

Lattice Semicon

Eli Lilly

Palantir Tech

Mirum Pharmaceuticals

ON Semiconductor

Grayscale Bitcoin Mini Trust ETF

Moving some stops to no green to red $SPDR S&amp;P Biotech(XBI.US) $CrowdStrike(CRWD.US)Source: Sunrise Trader

CrowdStrike

$SPDR S&amp;P Biotech(XBI.US) daily pullback to 50ma and bounce. A move and hold over the 10/21ma's if price wants it are next on my radar.Source: Sunrise Trader

$SPDR S&amp;P Biotech(XBI.US) my paydays sold for OK payday %. Still a day trade for now. I have swing plan ready.Source: Sunrise Trader

Don't sleep on Biotech 🧪 $SPDR S&amp;P Biotech(XBI.US)Source: TrendSpider

Novo Nordisk AS

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

The biotech sector is really like a roller coaster ride, with XBI seeing large capital outflows and LABU leveraged ETFs plummeting... Despite all analysts saying this sector is worth watching in 2026, why is the short-term performance so disappointing? After tasting the bitterness of volatility, I finally understand making money isn't that easy. But perhaps with more patience, we might still see a turnaround. Everyone, hold tight and keep watching.

Under the pressure of interest rate cuts, small-cap stocks like $SPDR S&amp;P Biotech(XBI.US) are rising much faster than large-cap stocks like $Alphabet(GOOGL.US)😂

Alphabet

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Alphabet - C

The impact of interest rate cuts on small and mid-cap biotech stocks in the US market is immediate$Direxion S&amp;P Biotech Bull 3X(LABU.US)$SPDR S&amp;P Biotech(XBI.US)